GLP1R and Stroke: The pooled analysis of primary and secondary endpoints showed that GLP-1 RAs significantly reduced the risk of stroke by 15 % (OR, 0.85(95 %CI: 0.77–0.93), P < 0.001), I2 = 0) (Fig. 2), nonfatal stroke by 13 % (OR, 0.87(95 %CI: 0.79–0.95), P < 0.01), I2 = 0) when compared with placebo.